Ranbaxy Labs - Q1CY12 Result update/ Estimate change - Centrum
26.05.12
Set back
Target Price: Rs464
CMP: Rs511
Downside: 9.2%
Strong proliferation in US business Ranbaxy Labs (RLL) has reported mastery than expected results due to higher margin, forex achievement on derivatives and lower tax provision. RLL reported 71%YoY tumour in revenues due to FTF opportunities of generic
[ Via: Equity Bulls | Read more... ]
